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ABSTRACT
Vitamin D is a pleiotropic molecule 
with a well-characterised immunomod-
ulatory activity in vitro; however, its 
potential clinical application in auto-
immune conditions has yet to be clari-
fied. Several authors have investigated 
the use of vitamin D as a disease-mod-
ifying anti-rheumatic drug (DMARD) 
in rheumatoid arthritis (RA), obtaining 
divergent conclusions. 
This systematic review summarises and 
critically analyses the findings of pa-
pers assessing the impact of vitamin D 
supplementation on pain relief, disease 
activity, functional status and flare rate. 
We conclude that the correction of hy-
povitaminosis D may have a beneficial 
effect on pain perception; moreover, 
the achievement of an adequate plasma 
vitamin D concentration obtained with 
high-dose regimens might evoke immu-
nomodulatory activities of vitamin D 
and favourably impact on disease con-
trol. Nevertheless, the current evidence 
is still not strong enough to support the 
use of cholecalciferol as a DMARD in 
RA, and further studies are required to 
clarify this issue.
Introduction
Vitamin D is a fat-soluble hormone, 
which is mainly involved in the regula-
tion of calcium/phosphate metabolism 
(1-3). In the last decades, the over-
whelming evidence that vitamin D re-
ceptor (VDR) is expressed not only by 
cognate vitamin D targets but also by 
other cell types and tissues allowed sev-
eral authors to postulate a broader role 
for vitamin D in human physiology than 
that already ascertained, i.e. the simple 
control of calcium/phosphate levels. 
The most convincing evidence in this 
sense has been obtained in the field of 
immunology. Firstly, the exposure to 
activated vitamin D affects monocytes 
and macrophages by enhancing their 
phagocytic, mycobactericidal, and tu-
mor-cell cytotoxic ability (4, 5), while 
at the same time limiting the production 
of crucial proinflammatory cytokines 
such as Interleukin 6 (IL-6) and tumour 
necrosis factor α (TNF-α) (6). More-
over, by down-regulating the expres-
sion of MHC II and costimulatory mol-
ecules, vitamin D suppresses antigen 
presentation and chemotactic capacity 
of monocytes and dendritic cells (DCs) 
(7, 8). 
The immunomodulatory effects of vita-
min D on the adaptive immune system 
are likewise substantial. On B cells, 
vitamin D acts by inhibiting their pro-
liferation, differentiation, and immuno-
globulin secretion (9); furthermore, it 
limits T cells cytotoxic activity (10) and 
drives the CD4+ differentiation towards 
the suppression of Th1 and Th17 subsets, 
while favouring the less inflammatory 
Th2 or Treg phenotype (11-13).  
Remarkably, in the specific context of 
rheumatoid arthritis (RA), vitamin D 
can suppress the in vitro proliferation 
of synoviocytes isolated from synovial 
tissue of RA or osteoarthritis patients. 
The production of proinflammatory 
cytokines is synergistically reduced by 
dexamethasone and the vitamin D ana-
logue, calcipotriol (14). These findings 
are in line with data from animal mod-
els. Indeed, synoviocytes derived from 
joints of rats with collagen-induced ar-
thritis show a decrease in IL-1β, IL-6, 
IL-8, and PGE2 production and a re-
duction of MMP-3, INOS, and Cox-2 
mRNA expression upon treatment with 
1,25(OH)2 vitamin D (15). Similarly, vi-
tamin D downregulates the production 
of matrix metalloproteinase (MMP)-1, 
MMP-3, and MMP-9 in human IL-1β-
stimulated synoviocytes (16).
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In line with these findings, it is reason-
able to postulate a potential role for 
vitamin D as an immune-regulator in 
the management of RA (17, 18). First 
evidences in support to this hypoth-
esis date back to more than 80 years 
ago. In 1935, Dreyer & Reed reported 
a clinical improvement of the disease 
with cholecalciferol 300000-500000 
IU per day (19); similarly favourable 
observations confirmed these findings 
in the following years. Since the avail-
ability of a plethora of highly effective 
drugs has dramatically changed the 
natural history of RA in the last two 
decades, someone trying to translate 
those early data into current practice 
would be simply unreasonable. Be-
sides, a new set of classification crite-
ria and different scores for disease ac-
tivity have been implemented. In brief, 
these remote studies cannot be consid-
ered more than a clue of the possible 
usefulness of vitamin D as a disease-
modifying drug in RA. Nonetheless, 
the demonstration of the effectiveness 
of vitamin D add-on to the standard of 
care for RA control might provide a 
novel inexpensive and well-tolerated 
therapeutic tool. The present study 
aims to systematically review the cur-
rent evidence supporting the potential 
use of vitamin D as a disease-modify-
ing anti-rheumatic drug (DMARD) for 
the management of RA.
Methods
We performed a systematic review of 
the literature looking for studies evalu-
ating the potential role of cholecalcifer-
ol as DMARD in RA. On 9th December 
2018, we interrogated Pubmed using 
the following string: “Vitamin D AND 
Rheumatoid Arthritis”. This search 
yielded 691 publications of potential 
relevance.
We applied the following inclusion 
criteria: 
•  Full-text paper 
•  English language available
•  Cohort study (prospective or retro-
spective), case-control study or ran-
domised controlled trial
•  The effect of vitamin D supplemen-
tation on different endpoints related 
to disease control in RA in human 
subjects
We applied the following exclusion 
criteria: 
•  Letters, case reports, reviews, ab-
stracts 
•  Studies in which the effect of chole-
calciferol on RA endpoints is not 
evaluated.
Retrieved studies were screened ac-
cording to inclusion and exclusion 
criteria by two of us (M.B. and P.P.S.); 
604 studies were excluded after the 
evaluation of the title, 74 after the revi-
sion of the abstract, and two after read-
ing the full text. Reasons for exclusion 
were recorded and are detailed in Fig-
ure 1. Eleven studies were eventually 
selected.
The following data were extracted from 
each study deemed worthy of inclusion: 
•  First author’s surname, journal and 
year of publication
•  Design
•  Sample size
• Concomitant ongoing DMARDs 
treatment




The main findings of all the selected 
papers are described in Table I.  
Results
Several of the studies included in this 
review evaluated the effect of vitamin 
D on pain relief in RA patients. At best, 
they suggest slight or moderate effica-
cy of cholecalciferol in reducing pain 
and improving subjective endpoints, 
independently of the regimen used (20, 
21). Buondonno et al. found a non-
significant trend (p=0.096) towards 
lower pain scores assessed by visual 
analogue scale (VAS) among patients 
treated with a single dose of cholecal-
ciferol 300000 IU along with metho-
trexate (15 mg/week) and prednisone 
(2-4 mg/day) in comparison with pla-
cebo. However, the small sample size 
(21 patients in the treatment group ver-
sus 18 patients in the placebo group) 
might have precluded reaching statis-
tical significance. In the same study, 
the authors demonstrated a significant 
improvement in the Global Health 
(GH) score at three months of patients 
treated with cholecalciferol (22). Con-
versely, in one publication by Hansen 
et al., the GH score was negatively af-
fected by vitamin D supplementation. 
The limited number of patients (11 pa-
tients in the vitamin D group versus 11 
patients in the control group), as well 
as the use of ergocalciferol rather than 
cholecalciferol, might explain this ap-
parent discrepancy (23). 
Furthermore, when objective measure-
ments and ambitious outcomes such as 
inflammatory markers reduction or dis-
ease activity improvement were consid-
ered, findings were even less consistent. 
In 1973, Brohult and Jonson (20) docu-
mented significant subjective and objec-
tive clinical improvement as well as de-
crease in the erythrocyte sedimentation 
rate (ESR) in 25 patients treated with 
very large doses (100000 IU daily) of 
cholecalciferol in comparison with 25 
placebo-controls. None of the patients 
included in this study was receiving 
DMARDs. More recently, the effects 
of cholecalciferol along with a con-
comitant DMARD treatment have been 
tested in a placebo-controlled trial (24). 
The supplementation with cholecalcif-
erol 50000 IU/week did not increase 
significantly the proportion of patients 
whose disease activity score 28 (DAS 
28) was improved at 12 weeks (24), yet 
a trend towards a better DAS28 in the 
treatment group and a negative correla-
tion between 25(OH)vitamin D levels 
and DAS28 was observed. However, in 
this study: i. Patients were treated with 
variable DMARDs strategies; ii. Base-
Fig. 1. Flowchart of the study selection process. 
In figure 1, we reported the flowchart represent-
ing the process of selection of the studies includ-
ed in this systematic review. 
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Table I. Summary of review findings. The table reports the main findings of all the papers included in the present review. 
Authors  Journal and year Design of the trial Patients DMARD Cholecalciferol Endpoints Main findings
    treatment regimen 
Brohult et al.20 Scand J  Double-blinded, 25 (study group) None Cholecalciferol 100000 ESR reduction, objective Cholecalciferol group showed
 Rheumatol 1973 randomised,  vs.  IU/daily for 1 year and subjective a significant objective and
  placebo-controlled 25 (control group)    improvement subjective improvement and a
  clinical trial     reduction of ESR 
  
Andjelkovic et al.27 Clin Exp Open label trial 19 RA patients  MTX ± PDN 2 μg/day alphacalcidiol Disease activity (measured Alphacalcidiol improves
 Rheumatol 1999  with active RA  for 3 months by RAI, Lee index, tender  disease activity
      and swollen joint) 
Gopinath et al.21 Int J Rheum Open-label 59 (study arm) MTX + SSZ + calcium carbonate 1000  Pain relief assessed by Vitamin D supplementation in
 Dis 2011  Randomised vs. HCQ + NSAIDs mg + cholecalciferol VAS score previously DMARD naïve early
  Controlled Trial 62 (control arm)  500 IU/day for 3 months  RA patients significantly
   early RA patients,  vs.  improves pain relief
   DMARD naive  calcium carbonate 1000   
     mg alone  
Salesi et al.24  Rheumatol  Double-blinded, 50 (study arm) MTX ± HCQ Cholecalciferol 50000 Proportion of patients with No significant improvement in
 Int 2012 randomised, vs. and/or PDN IU/week for 12 weeks a 0.6 and 1.2 improvement vitamin D treated patients
  placebo-controlled 48 (control arm)  vs. in DAS28
  clinical trial RA patients  placebo   
Dehghan et al.30 Z Rheumatol 2013 Double-blinded,  40 (study arm) MTX and/or Cholecalciferol 50000 Number of flares in patients No statistical reduction in the
  randomised, vs. HCQ ± PDN IU/week for 6 months in clinical remission number of flares or in
  placebo-controlled 40 (control arm)  vs.  prednisolone dose required
  clinical trial RA patients in  placebo 
   remission  
Hansen et al.23 J Clin  Double-blinded, 11 (study arm) Mixed not Ergocalciferol 50000 DAS28, SF-36, HAQ, Vitamin D supplementation
 Rheumatol 2014 randomised, vs.  specified IU three times weekly Patient’s and Physician’s worsen SF-36 and patient’s
  placebo-controlled 11 (control arm)  for four weeks, then GH global assessment.
  clinical trial   50000 IU twice monthly  No impact on DAS28 
     for 11 months
     vs. 
     placebo   
Yang et al.29 Exp Ther Randomised  168 (Normal Not specified Alphacalcidiol 0.25 RA recurrence The recurrence rate was
 Med 2015 controlled  vitamin D  μg/daily for 8 weeks  significantly lower in normal
  open-label trial  unsupplemented)    vitamin D group vs.
   vs.    unsupplemented; a
   84 (low vitamin D    non-significant trend towards
   supplemented)    lower recurrence rate was
   vs.    shown for supplemented
   88 (low vitamin D    vs. unsupplemented arms
   unsupplemented)
   RA patients in
   remission      
Chandrashekara et al.25 Int J Rheum  Randomised open 73 with residual MTX and/or Cholecalciferol 60000 DAS28, VAS pain, The addition of vitamin D to
 Dis 2015 label trial disease activity LFN and/or IU/week for 6 weeks TJC and SJC the ongoing treatment 
   (DAS28ESR >2.6) HCQ then 60000 IU/month  improves disease activity
   and low vitamin D  for 3 months  measured as DAS28, TJC
   levels    and SJC
Buondonno et al.22 PlosONE 2017 Double-blinded, 21 (study arm) MTX + PDN Single cholecalciferol DAS28, CRP, ESR, VAS Cholecalciferol improves GH
  randomised, vs.  300000 IU dose pain, GH, HAQ at 3 months; no effect on
  placebo-controlled 18 (placebo arm)  vs. placebo  other parameters
  clinical trial early RA patients  
Soubrier et al.28 Clin Exp  Double-blinded, 29 (study arm) Stable DMARD Cholecalciferol 100000 HAQ, VAS pain, SF-36, Cholecalciferol improves
 Rheumatol 2018 randomised, vs. regimen IU single dose DAS28, ESR, CRP HAQ, ESR and CRP;
  placebo-controlled 30 (placebo arm)  vs.   no effect on the other
  clinical trial RA patients  placebo  parameters 
   DAS28 >2.6     
Adami et al.26 Mod Rheumatol Open label trial 61 patients with Mixed regimen,  Cholecalciferol 100000 VAS pain, DAS28-CRP Correction of hypovitaminosis
 2018  active RA  stable during monthly for 3 months  D improves pain;
   (DAS28 >2.6) the trial   supplementation of patients
   on stable DMARD    without vitamin D deficiency in 
       associated to an improvement
       on DAS28-CRP
RA: rheumatoid arthritis; DMARD: disease-modifying anti-rheumatic drug; DAS: Disease Activity Score; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; MTX: methotrexate; 
SSZ: sulfasalazine; HCQ: hydroxychloroquine; PDN: prednisone; NSAID: non-steroidal anti-inflammatory drugs; LFN: leflunomide; IU: international units; VAS: visual analogue scale; RAI: 
Ritchie articular index; SF-36: short form health survey; HAQ: Health Assessment Questionnaire; GH: global health assessment; TJC: tender joints count; SJC: swollen joints count.
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line vitamin D levels were well above 
the lower normal limit both among pa-
tients assigned to active treatment and 
in controls, which is rather uncommon 
in RA patients; iii. Post-treatment in-
crease of 25(OH) vitamin D concentra-
tion was minimal (107 vs. 125 nmol/L), 
suggesting suboptimal compliance and/
or adequacy of the regimen used. 
As mentioned above, Buondonno et al. 
showed an improvement in the patients’ 
GH score but failed to demonstrate the 
additional advantage of a single load-
ing dose of 300000 IU cholecalciferol 
on the disease activity (22). 
In contrast, a recent open-label inter-
ventional study including RA patients 
with residual disease activity (DAS28 
>2.6) reached substantially different 
conclusions. Indeed, adding cholecal-
ciferol 60000 IU/week for six weeks 
followed by 60000/month to a stable 
DMARD treatment significantly in-
creased the 25(OH)vitamin D levels 
measured at three months from 10.05 
ng/ml (25.08 nmol/L) to 57.21 ng/ml 
(142.79 nmol/L). Importantly, this raise 
was mirrored by a significant decrease 
in the VAS pain, tender and swollen 
joints counts, and DAS28 (either calcu-
lated with ESR or CRP) (25). 
A recent paper from the Study Group 
on Osteoporosis and Metabolic Skel-
etal Diseases of the Italian Society of 
Rheumatology (SIR) reached similar 
conclusions (26). None of the 61 pa-
tients studied were receiving vitamin 
D at the time of recruitment and all 
had active RA despite a stable dose of 
DMARD. They were given 100000 IU 
of cholecalciferol monthly over a three 
months period. The study population 
was split according to the baseline vi-
tamin D level observed, using 20 ng/
ml as the cut-off value to define vitamin 
D deficiency; mean serum 25(OH) vi-
tamin D concentration improved from 
13±5 to 32±12 ng/mL and from 29±7 
to 41±10 ng/mL in patients with and 
without vitamin D deficiency (<20 ng/
ml) at baseline, respectively. Overall, 
pain improved (with VAS decreasing 
from 5.8 to 4.8±2.3), but statistical sig-
nificance was reached only in the vita-
min D deficient group. Likewise, mean 
DAS28-CRP at three months decreased 
numerically but not significantly in the 
population as a whole (from 3.8±0.9 
to 3.2±1.2), but the observed improve-
ment reached statistical significance in 
the vitamin D-deficient group. 
A different vitamin D analogue, alfa-
calcidol (or 1-hydroxycholecalciferol), 
has been tested as potential DMARD 
in a study published in 1999 by And-
jelkovic et al. These authors evaluated 
the effect of the add-on of 2 μg/day of 
alfacalcidol to methotrexate (10 mg/
week) with or without concomitant 
prednisone (10 mg/day). After three 
months of alfacalcidol therapy, 89% 
of the patients had improved. A signifi-
cant decrease in the number of swol-
len and tender joints was demonstrated 
in all RA patients, being paralleled by 
the improvement in both the Ritchie 
Articular Index and the Lee Index, and 
associated with a significant decline of 
ESR and CRP (27). 
A recently published study also evalu-
ated the effect of cholecalciferol sup-
plementation on the functional status of 
patients with RA assessed by the Health 
Assessment Questionnaire (HAQ) (28). 
No significant differences between vi-
tamin D- and placebo-treated groups 
were evident when the outcome was as-
sessed without adjustments; however, 
adjusting for age, gender, season, and 
initial vitamin D status, the between-
group difference in the HAQ score at 
six months achieved statistical signifi-
cance (Vitamin D group -0.03±0.23 vs. 
0.08±0.25 placebo group, p=0.046).
Finally, the effectiveness of vitamin D 
supplementation on the prevention of 
RA flares has been evaluated in two dif-
ferent studies. In 2015, Yang et al. dem-
onstrated that RA patients in remission 
are at higher risk of disease relapse in 
the presence of a coexisting vitamin D 
deficiency, defined by 25(OH) vitamin 
D plasma concentration <30 ng/ml, in 
comparison to patients not vitamin D 
deficient. However, the correction of 
the low baseline levels of vitamin D by 
alfacalcidol supplementation (0.25 μg, 
twice a day) did not reduce the rate of 
recurrence as compared to the unsup-
plemented group (29). Similarly, De-
hgahn et al. failed to prove a protective 
role for cholecalciferol supplementa-
tion with regard to the risk of flares in 
RA patients (30).
It is relevant to note that the favourable 
safety profile of cholecalciferol-based 
regimens was confirmed in all the stud-
ies (above) in which they were used, 
independently of the dose. This did 
not hold true for alfacalcidol, whose 
highest dose was associated with an 
increased risk of asymptomatic hyper-
calciuria (27).
Discussion
Vitamin D is a pleiotropic molecule 
with well-characterised and consistent-
ly proven immunoregulatory activity in 
vitro, which to date has failed to trans-
late into convincing efficacy in humans 
with dysregulated immunity. 
Here, we have reviewed the current 
literature on the potential use of vita-
min D as a DMARD in RA manage-
ment, adopting a systematic approach. 
We do not think we can conclude ei-
ther in favour or against a significant 
DMARD activity by vitamin D, since 
the results and conclusions of the stud-
ies we analysed were, to a large extent, 
divergent. Several reasons can explain 
the observed discrepancies, including:
1- Small sample size of interventional 
trials;
2- Enrolment of patients at diverse 
disease stages, with variable dis-
ease duration and multiple ongoing 
DMARD regimens;
3- Choice of different outcomes and 
endpoints;
4- Use of different molecules and dos-
ages, with significant variation over 
the years.
Nevertheless, we do believe that some 
plausible considerations can be made 
on this topic.
First, to properly evaluate the effects of 
vitamin D supplementation in RA, it is 
worth to keep in mind that the mecha-
nisms underlying pain and inflamma-
tion overlap only partially. Although 
inflammation is partially responsible 
for pain perception in RA, patients 
with a long-standing disease may de-
velop central sensitisation (31) and 
neuropathic pain (32). In this context, 
vitamin D could play a relevant role, 
since hypovitaminosis D has been as-
sociated with neuropathic pain in RA 
(33). Therefore, the correction of vi-
tamin D deficiency might reasonably 
347Clinical and Experimental Rheumatology 2020
Vitamin D in rheumatoid arthritis / M. Bellan et al.
improve the neuropathic pain in RA, as 
already demonstrated in patients with 
type 2 diabetes mellitus (34, 35). There 
is substantial agreement on the effica-
cy of cholecalciferol supplementation 
to relieve pain, even at relatively low 
doses. In this context, the correction 
of hypovitaminosis D in RA patients is 
likely accompanied by the additional 
advantage of reducing pain, as sup-
ported by the observations of Adami et 
al. (26), who showed a beneficial effect 
on the VAS pain only in patients with 
a baseline vitamin D deficiency. In the 
presence of a satisfactory vitamin D 
status, the contribution of the hypovita-
minosis D to neuropathic pain is prob-
ably negligible, thus explaining why it 
lacks efficacy. 
Improvement of the disease activity im-
plies a broader effect on objective pa-
rameters, such as inflammatory markers 
and joint involvement, which globally 
reflect the contribution of systemic in-
flammation. In the study mentioned 
above, a significant improvement of the 
DAS28-CRP was observed only among 
patients with higher vitamin D plasma 
levels, suggesting that the immunoreg-
ulatory activity of vitamin D prob-
ably requires greater 25(OH)vitamin D 
concentrations. Furthermore, in all the 
studies reporting a beneficial effect of 
cholecalciferol supplementation on in-
flammatory markers or disease activity 
scores, higher cumulative doses were 
used (20, 25), in comparison to trials 
that did not meet these endpoints (22). 
As mentioned above, only one study 
using high cumulative cholecalciferol 
doses failed to demonstrate the ben-
efit of vitamin D supplementation on 
the disease activity (24); nonetheless, 
the minimal increase of the vitamin D 
plasma concentration from baseline is a 
hint for low compliance of patients to 
the prescribed regimen.
Taken together, these findings suggest 
that RA patients could take advan-
tage from vitamin D supplementation, 
both in terms of pain relief (when hy-
povitaminosis D is corrected) and im-
mune system regulation (when higher 
25(OH)vitamin D plasma concentra-
tions are obtained using high-doses 
regimens). The problematic translation 
of the experimental findings to human 
disease can be explained by the inade-
quacy of an in vitro system to faithfully 
replicate the complexity of vitamin D 
metabolism in vivo. Indeed, this is not 
only influenced by the systemic level 
of cholecalciferol activation but also 
by the activity of the inhibiting enzyme 
CYP24A1, whose role might be more 
relevant than predicted in the past. 
Another crucial step occurring in vivo 
is the local activation of vitamin D, 
probably more common in the presence 
of sufficiently high levels of cholecal-
ciferol. Macrophages (36) and DCs 
(37) express CYP27B1, the activating 
enzyme of the intermediate metabolite 
25(OH) vitamin D, which directly ac-
tivates 25(OH) vitamin D in significant 
amount ex vivo (38). 
25(OH) vitamin D concentration in the 
synovial fluid is approximately double 
the plasmatic level (39), and its anti-
inflammatory effect is seen at about 
50-100 nM in the presence of activating 
cells like APCs. Thus, the plasma con-
centration required for ensuring bone 
health is very likely too low to enhance 
any immunomodulatory effects (40). 
Therefore, only by using high doses 
of cholecalciferol, which seem well 
tolerated and safe, levels of vitamin D 
sufficiently high to enable its immuno-
suppressive effect locally on synovial 
tissue could be reached (41). 
Finally, the response to vitamin D in 
vivo may also be influenced by VDR 
polymorphisms. Since the TaqI and 
FokI polymorphisms have been previ-
ously associated with RA susceptibility 
(42), it is plausible that they might also 
play a role in regulating the individual 
response to cholecalciferol supplemen-
tation.
Concerning the efficacy of different 
compounds, only one study has so far 
investigated the use of ergocalciferol, 
concluding that this is not advisable 
based on its ineffectiveness (23). On 
the contrary, alfacalcidol looks a prom-
ising agent; being an already active 
form of vitamin D, however, it may be 
burdened by a higher risk of hypercal-
caemia and hypercalciuria than chole-
calciferol, which should probably be 
considered the first-line agent in sub-
jects with normal renal function (27). 
Regarding RA flares, despite none of 
the two studies assessing vitamin D ef-
ficacy revealed a significant beneficial 
effect, a recent meta-analysis suggests a 
potential role for vitamin D in this con-
text. In fact, while no individual study 
met the endpoint, the cumulative anal-
ysis of the two study populations was 
close to significant. Further studies are 
required to elucidate this specific issue 
better (43).
Finally, it should be pointed out that the 
ability of vitamin D to suppress second-
ary hyperparathyroidism might be par-
tially compromised in patients affected 
by autoimmune diseases (44), and this 
fact may contribute to the development 
of RA-related osteoporosis. Since hy-
povitaminosis D is highly prevalent in 
autoimmune conditions (45-48), the 
correction of hypovitaminosis D is 
paramount in the management of RA, 
even if the best regimen to be used is 
still debated (49-51).
We have to acknowledge some limita-
tions: first of all, our systematic review 
is focused on a topic which has recently 
been explored by a meta-analysis (43), 
including 5/11 of the papers considered 
in the present paper. However, the find-
ings of the two papers are consistent.
Moreover, the limitations underpinned 
when discussing the studies selected 
obviously affect the reliability of our 
findings. Patient population, outcome 
definitions and vitamin D schemes 
change across different studies, making 
them difficult to be compared. Finally, 
the largest part of evidences belongs to 
studies with small sample size, which 
might have affected the power of the 
findings.
In conclusion, a potential role for 
cholecalciferol in the management 
of RA can be hypothesised, although 
the doses required to evoke the im-
munomodulatory effects of vitamin D 
might be significantly higher than those 
currently used for hypovitaminosis cor-
rection. Despite the available evidence 
is not strong enough to support the use 
of cholecalciferol as a DMARD in RA 
and further studies are required to elu-
cidate this aspect better, the achieve-
ment of an adequate vitamin D status 
in this context is likely beneficial and 
should be given primary importance in 
the management of RA patients. 
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